Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy - PubMed (original) (raw)
. 2013 Apr 23;28(1):17-23.
doi: 10.5301/JBM.2012.9580.
Rita F Abi Raad, Irene Kuter, Marek Ancukiewicz, Lisa Roberts, Natalie Solomon, Taylor Ngo, Heather Borick, Paula Ryan, Beverly Moy, Michele Gadd, Jo Chien, Jerry Younger, Barbara Smith, Alphonse G Taghian, Lyndsay Harris
Affiliations
- PMID: 23015398
- DOI: 10.5301/JBM.2012.9580
Free article
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
Rimoun R Boutrus et al. Int J Biol Markers. 2013.
Free article
Abstract
Aim: To explore the significance of circulating tumor cells (CTCs) detection in the course of preoperative chemotherapy (PC) and their effect on the outcomes.
Methods: Fifty-five patients with stage II/III invasive breast cancer were enrolled into a preoperative clinical trial. Patients were given PC with sequential single-agent doxorubicin and paclitaxel vs paclitaxel followed by doxorubicin. Blood samples (8 mL) were collected from patients before PC, after each phase, and at 6 months intervals during follow-up. Peripheral blood mononuclear cells were isolated and enriched for epithelial cells. Quantitative RT-PCR was used to determine the presence of cytokeratin 19 (CK19) mRNA. Samples were considered positive when the PCR curve crossed the standard threshold curve.
Results: After the first phase of chemotherapy, there was a 59% overall reduction in the median tumor volume. The percentage of volume reduction did not differ between patients who presented with detectable CTCs at baseline and those who did not (p=0.89). After the second phase of chemotherapy, there was a further decrease in the median tumor volume to 93% from baseline. There was no correlation between the lack of response and the presence of CTCs either after the first (p=0.36) or second (p=0.5391) phases of PC. The presence of CTCs was a predictor of local or distant relapse (p=0.0411). The detection of CTCs did not affect overall survival (p=0.2569).
Conclusion: CTCs can be used as predictors of relapse after definitive treatment of locally advanced breast cancer; however, CTCs detection in peripheral blood during the course of PC does not implicate a particular pattern of response to treatment.
Similar articles
- Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, Jin CG, Wang XC. Chen Y, et al. Int J Biol Markers. 2010 Apr-Jun;25(2):59-68. doi: 10.1177/172460081002500201. Int J Biol Markers. 2010. PMID: 20586026 - Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
Park HS, Han HJ, Lee S, Kim GM, Park S, Choi YA, Lee JD, Kim GM, Sohn J, Kim SI. Park HS, et al. Yonsei Med J. 2017 Jan;58(1):19-26. doi: 10.3349/ymj.2017.58.1.19. Yonsei Med J. 2017. PMID: 27873491 Free PMC article. - Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D. Xenidis N, et al. J Clin Oncol. 2009 May 1;27(13):2177-84. doi: 10.1200/JCO.2008.18.0497. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332733 - Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis.
Saloustros E, Mavroudis D. Saloustros E, et al. Future Oncol. 2010 Feb;6(2):209-19. doi: 10.2217/fon.09.147. Future Oncol. 2010. PMID: 20146580 Review. - CTCs in primary breast cancer (II).
Saloustros E, Mavroudis D. Saloustros E, et al. Recent Results Cancer Res. 2012;195:187-92. doi: 10.1007/978-3-642-28160-0_17. Recent Results Cancer Res. 2012. PMID: 22527506 Review.
Cited by
- PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER.
Botnariuc I, Ilie SM, Trifanescu OG, Bacinschi XE, Curea F, Anghel RM. Botnariuc I, et al. Acta Endocrinol (Buchar). 2017 Apr-Jun;13(2):209-214. doi: 10.4183/aeb.2017.209. Acta Endocrinol (Buchar). 2017. PMID: 31149175 Free PMC article. Review. - Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity.
McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. McInnes LM, et al. Front Oncol. 2015 Feb 26;5:42. doi: 10.3389/fonc.2015.00042. eCollection 2015. Front Oncol. 2015. PMID: 25767772 Free PMC article. Review. - Prospects for Fluorescence Molecular In Vivo Liquid Biopsy of Circulating Tumor Cells in Humans.
Niedre M. Niedre M. Front Photon. 2022;3:910035. doi: 10.3389/fphot.2022.910035. Epub 2022 May 8. Front Photon. 2022. PMID: 39508030 Free PMC article. - Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.
Yan WT, Cui X, Chen Q, Li YF, Cui YH, Wang Y, Jiang J. Yan WT, et al. Sci Rep. 2017 Mar 24;7:43464. doi: 10.1038/srep43464. Sci Rep. 2017. PMID: 28337998 Free PMC article. - Breast cancer as a systemic disease: a view of metastasis.
Redig AJ, McAllister SS. Redig AJ, et al. J Intern Med. 2013 Aug;274(2):113-26. doi: 10.1111/joim.12084. J Intern Med. 2013. PMID: 23844915 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical